Gryaznov Sergei 4

What Happened
Sergei Gryaznov, Chief Scientific Officer of MAIA Biotechnology (MAIA), reported an acquisition of 2,000 common shares on 2026-06-01. The shares were acquired at $1.34 per share for a total transaction value of $2,690. This was a direct purchase (transaction code P), not a sale or option exercise.

Key Details

• Transaction date: 2026-06-01; Report filed: 2026-06-02 (timely filing).
• Transaction type: Purchase (code P) — 2,000 shares at $1.34 each.
• Total value: $2,690.
• Shares owned after transaction: Not specified in the provided filing details.
• No footnotes, 10b5-1 plan, option exercise, gift, or tax-withholding indicated in the reported transaction.

Context
This was a straightforward open-market/private purchase rather than a derivative transaction or tax-related disposition. Insider purchases are often watched by investors as a potential signal of confidence, but this is a small, single transaction and should be considered alongside other filings and company developments.